{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T08:39:30Z","timestamp":1792744770904,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T00:00:00Z","timestamp":1763164800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T00:00:00Z","timestamp":1763164800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100014382","name":"Ipsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncol Ther"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40487-025-00393-9","type":"journal-article","created":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T01:57:51Z","timestamp":1763171871000},"page":"253-268","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Two-Stage Estimation of Overall Survival in the Phase 3 CheckMate 9ER Trial, Adjusting for the Impact of Subsequent Therapy"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3084-8654","authenticated-orcid":false,"given":"Marc-Oliver","family":"Grimm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Karim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venediktos","family":"Kapetanakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mickael","family":"Lothgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Ogareva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pragya","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Truscott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2412-1563","authenticated-orcid":false,"given":"Camillo","family":"Porta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,15]]},"reference":[{"issue":"9","key":"393_CR1","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa2026982","volume":"384","author":"TK Choueiri","year":"2021","unstructured":"Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2021;384(9):829\u201341. https:\/\/doi.org\/10.1056\/NEJMoa2026982.","journal-title":"N Engl J Med"},{"key":"393_CR2","unstructured":"US Food and Drug Administration. FDA approves nivolumab plus cabozantinib for advanced renal cell carcinoma. January 22, 2021. Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-nivolumab-plus-cabozantinib-advanced-renal-cell-carcinoma (Accessed July 02, 2025)."},{"key":"393_CR3","unstructured":"Ipsen. European Commission approves Cabometyx\u00ae in combination with Opdivo\u00ae as a first-line treatment for patients living with advanced renal cell carcinoma. Available at: https:\/\/ipsen.com\/websites\/Ipsen_Online\/wp-content\/uploads\/2021\/03\/30214134\/Ipsen-Cabo-Opdivo-EMA-Release.pdf (Accessed July 02, 2025)."},{"issue":"7","key":"393_CR4","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/S1470-2045(22)00290-X","volume":"23","author":"RJ Motzer","year":"2022","unstructured":"Motzer RJ, Powles T, Burotto M, Escudier B, Bourlon MT, Shah AY, et al. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. Lancet Oncol. 2022;23(7):888\u201398. https:\/\/doi.org\/10.1016\/S1470-2045(22)00290-X.","journal-title":"Lancet Oncol"},{"issue":"6_suppl","key":"393_CR5","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1200\/JCO.2022.40.6_suppl.350","volume":"40","author":"T Powles","year":"2022","unstructured":"Powles T, Choueiri TK, Burotto M, Escudier B, Bourlon MT, Shah AY, et al. Final overall survival analysis and organ-specific target lesion assessments with two-year follow-up in CheckMate 9ER: nivolumab plus cabozantinib versus sunitinib for patients with advanced renal cell carcinoma. J Clin Oncol. 2022;40(6_suppl):350. https:\/\/doi.org\/10.1200\/JCO.2022.40.6_suppl.350.","journal-title":"J Clin Oncol"},{"issue":"5","key":"393_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102994","volume":"9","author":"T Powles","year":"2024","unstructured":"Powles T, Burotto M, Escudier B, Apolo AB, Bourlon MT, Shah AY, et al. Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial. ESMO Open. 2024;9(5):102994. https:\/\/doi.org\/10.1016\/j.esmoop.2024.102994.","journal-title":"ESMO Open"},{"key":"393_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.09.006","author":"RJEB Motzer","year":"2025","unstructured":"Motzer RJEB, Burotto M, Powles T, Apolo AB, Bourlon MT, Shah AY, et al. Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial. Ann Oncol. 2025. https:\/\/doi.org\/10.1016\/j.annonc.2025.09.006.","journal-title":"Ann Oncol"},{"issue":"1","key":"393_CR8","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12874-019-0709-9","volume":"19","author":"NR Latimer","year":"2019","unstructured":"Latimer NR, Abrams KR, Siebert U. Two-stage estimation to adjust for treatment switching in randomised trials: a simulation study investigating the use of inverse probability weighting instead of re-censoring. BMC Med Res Methodol. 2019;19(1):69. https:\/\/doi.org\/10.1186\/s12874-019-0709-9.","journal-title":"BMC Med Res Methodol"},{"key":"393_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmorw.2024.100027","volume":"3","author":"R Frazer","year":"2024","unstructured":"Frazer R, McGrane J, Challapalli A, Ratnayake G, Malik J, Forde C, et al. Real-world patterns of treatment and response in metastatic renal cell carcinoma: a multicentre UK-wide review with UK Renal Oncology Collaborative (UK ROC). ESMO Real World Data Digit Oncol. 2024;3:100027. https:\/\/doi.org\/10.1016\/j.esmorw.2024.100027","journal-title":"ESMO Real World Data Digit Oncol"},{"key":"393_CR10","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.euros.2022.12.015","volume":"49","author":"NJ Shah","year":"2023","unstructured":"Shah NJ, Sura SD, Shinde R, Shi J, Singhal PK, Robert NJ, et al. Real-world treatment patterns and clinical outcomes for metastatic renal cell carcinoma in the current treatment era. Eur Urol Open Sci. 2023;49:110\u20138. https:\/\/doi.org\/10.1016\/j.euros.2022.12.015.","journal-title":"Eur Urol Open Sci"},{"issue":"2","key":"393_CR11","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.clgc.2023.09.009","volume":"22","author":"E Esterberg","year":"2024","unstructured":"Esterberg E, Iyer S, Nagar SP, Davis KL, Tannir NM. Real-world treatment patterns and clinical outcomes among patients with advanced renal cell carcinoma. Clin Genitourin Cancer. 2024;22(2):115\u201325.e3. https:\/\/doi.org\/10.1016\/j.clgc.2023.09.009.","journal-title":"Clin Genitourin Cancer"},{"issue":"17_suppl","key":"393_CR12","doi-asserted-by":"publisher","first-page":"LBA4501","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA4501","volume":"41","author":"BI Rini","year":"2023","unstructured":"Rini BI, Plimack ER, Stus V, Gafanov R, Waddell T, Nosov D, et al. Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell. J Clin Oncol. 2023;41(17_suppl):LBA4501. https:\/\/doi.org\/10.1200\/JCO.2023.41.17_suppl.LBA4501.","journal-title":"J Clin Oncol"},{"key":"393_CR13","doi-asserted-by":"crossref","unstructured":"Latimer NR, Abrams KR. NICE DSU Technical Support Document 16: adjusting survival time estimates in the presence of treatment switching. London 2014.","DOI":"10.1016\/j.jval.2013.08.013"},{"issue":"11","key":"393_CR14","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1200\/JCO.23.01569","volume":"42","author":"RJ Motzer","year":"2024","unstructured":"Motzer RJ, Porta C, Eto M, Powles T, Grunwald V, Hutson TE, et al. Lenvatinib plus pembrolizumab versus sunitinib in first-line treatment of advanced renal cell carcinoma: final prespecified overall survival analysis of CLEAR, a phase III study. J Clin Oncol. 2024;42(11):1222\u20138. https:\/\/doi.org\/10.1200\/JCO.23.01569.","journal-title":"J Clin Oncol"},{"key":"393_CR15","unstructured":"R Development Core Team. R: a language and environment for statistical computing. 4.2.3 ed. Vienna, Austria: R Foundation for statistical computing; 2023."},{"issue":"25","key":"393_CR16","doi-asserted-by":"publisher","first-page":"2957","DOI":"10.1200\/jco.22.00868","volume":"40","author":"WK Rathmell","year":"2022","unstructured":"Rathmell WK, Rumble RB, Van Veldhuizen PJ, Al-Ahmadie H, Emamekhoo H, Hauke RJ, et al. Management of metastatic clear cell renal cell carcinoma: ASCO guideline. J Clin Oncol. 2022;40(25):2957\u201395. https:\/\/doi.org\/10.1200\/jco.22.00868.","journal-title":"J Clin Oncol"},{"issue":"8","key":"393_CR17","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.annonc.2024.05.537","volume":"35","author":"T Powles","year":"2024","unstructured":"Powles T, Albiges L, Bex A, Comperat E, Grunwald V, Kanesvaran R, et al. Renal cell carcinoma: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024;35(8):692\u2013706. https:\/\/doi.org\/10.1016\/j.annonc.2024.05.537.","journal-title":"Ann Oncol"},{"issue":"3","key":"393_CR18","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1200\/OP.22.00660","volume":"19","author":"EA Singer","year":"2023","unstructured":"Singer EA, Rumble RB, Van Veldhuizen PJ. Management of metastatic clear cell renal cell carcinoma: ASCO guideline Q&A. JCO Oncol Pract. 2023;19(3):127\u201331. https:\/\/doi.org\/10.1200\/OP.22.00660.","journal-title":"JCO Oncol Pract"},{"issue":"14","key":"393_CR19","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","volume":"384","author":"R Motzer","year":"2021","unstructured":"Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med. 2021;384(14):1289\u2013300. https:\/\/doi.org\/10.1056\/NEJMoa2035716.","journal-title":"N Engl J Med"},{"issue":"12","key":"393_CR20","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","volume":"380","author":"BI Rini","year":"2019","unstructured":"Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1116\u201327. https:\/\/doi.org\/10.1056\/NEJMoa1816714.","journal-title":"N Engl J Med"},{"issue":"10","key":"393_CR21","doi-asserted-by":"publisher","first-page":"3475","DOI":"10.1038\/s41591-025-03867-5","volume":"31","author":"BI Rini","year":"2025","unstructured":"Rini BI, Plimack ER, Stus V, Gafanov R, Waddell T, Nosov D, et al. Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial. Nat Med. 2025;31(10):3475\u201384. https:\/\/doi.org\/10.1038\/s41591-025-03867-5.","journal-title":"Nat Med."},{"issue":"5_suppl","key":"393_CR22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.5_suppl.439","volume":"43","author":"RJ Motzer","year":"2025","unstructured":"Motzer RJ, Escudier B, Burotto M, Powles T, Apolo AB, Bourlon MT, et al. Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): final follow-up results from the CheckMate 9ER trial. J Clin Oncol. 2025;43(5_suppl):439. https:\/\/doi.org\/10.1200\/JCO.2025.43.5_suppl.439.","journal-title":"J Clin Oncol"},{"key":"393_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.eucr.2023.102561","volume":"51","author":"K McGillivray","year":"2023","unstructured":"McGillivray K, McKenna R, Oades G, Rodger F. Spontaneous regression of metastatic renal cancer and improvement in IMDC risk criteria prior to cytoreductive nephrectomy. Urol Case Rep. 2023;51:102561. https:\/\/doi.org\/10.1016\/j.eucr.2023.102561.","journal-title":"Urol Case Rep"},{"issue":"2","key":"393_CR24","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1111\/j.1464-410x.1989.tb05147.x","volume":"63","author":"RT Oliver","year":"1989","unstructured":"Oliver RT, Nethersell AB, Bottomley JM. Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma. Br J Urol. 1989;63(2):128\u201331. https:\/\/doi.org\/10.1111\/j.1464-410x.1989.tb05147.x.","journal-title":"Br J Urol"}],"container-title":["Oncology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-025-00393-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40487-025-00393-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-025-00393-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T08:05:16Z","timestamp":1792742716000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40487-025-00393-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,15]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["393"],"URL":"https:\/\/doi.org\/10.1007\/s40487-025-00393-9","relation":{},"ISSN":["2366-1070","2366-1089"],"issn-type":[{"value":"2366-1070","type":"print"},{"value":"2366-1089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,15]]},"assertion":[{"value":"8 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Marc-Oliver Grimm received research grants from Bayer Health Care, Bristol Myers Squibb, and Intuitive Surgical; received honoraria from Astellas, Astra Zeneca, Bayer, Bristol Myers Squibb, Ipsen, Janssen Cilag, Merck, MSD, Novatis, and Telix; participated on Data Safety Monitoring or Advisory Boards for Astellas, Astra Zeneca, Bayer Health Care, Bristol Myers Squibb, Eisai, Gilead, Ipsen, Janssen Cilag, Kranus, Merck Serono, MSD, Novartis, Pfizer Pharma, Recordati, Roche Pharma, and Telix. Emma Karim, Mickael Lothgren, and Alessia Ogareva are employees of Ipsen. Venediktos Kapetanakis, Pragya Shukla, and James Truscott are employees of Evidera, which was contracted by Ipsen to conduct the data analysis. Camillo Porta acted as a remunerated consultant or speaker for Angelini Pharma, AstraZeneca, BMS, Eisai, Exelixis, Genenta, GenMab, Ipsen, Merck Serono, and MSD; as a Protocol Steering Committee member for Eisai and MSD; and as a Protocol Safety Monitoring Board member for Genenta.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The results presented in this manuscript are based on data from the published CheckMate 9ER trial. All procedures were conducted in accordance with Good Clinical Practice guidelines defined by the International Council for Harmonisation. Enrolled patients provided written informed consent according to the principles of the Declaration of Helsinki. Informed consent was obtained from all individual participants included in the original trial. International review board number 930112125. The results presented in this manuscript are based on published studies. Informed consent was obtained from all individual participants included in the CheckMate 9ER trial (ClinicalTrials.gov identifier NCT03141177).","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}